Similar Search Results

Estimating the Effect of Changes in Body Mass Index on Health State Preferences

Hakim, Zafar; Wolf, Anne; Garrison, Louis P. - In: PharmacoEconomics 20 (2002) 6, pp. 393-404

Objective: To investigate the effect of changes in body mass index (BMI) on health state preferences (HSP). Design: Multiple regression analysis on pooled data from a clinical study, predicting final HSP as a function of changes in BMI and initial HSP, controlling for age and gender. Subgroup...

Persistent link: https://www.econbiz.de/10005243200

Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus

Maetzel, Andreas; Ruof, Jorg; Covington, Melva; Wolf, Anne - In: PharmacoEconomics 21 (2003) 7, pp. 501-512

Objective: To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard...

Persistent link: https://www.econbiz.de/10005243210

Socioeconomic Issues Affecting the Treatment of Obesity in the New Millennium

Martin, Louis F.; Robinson, Alex; Moore, Barbara J. - In: PharmacoEconomics 18 (2000) 4, pp. 335-353

The prevalence of obesity among the populations of most developed countries has increased to such an extent that the … healthcare and social security/disability system will accumulate direct and indirect costs related to obesity that will be more … appropriate medical insurance reimbursement for the treatment of obesity. Societal prejudices, inability of governmental agencies …

Persistent link: https://www.econbiz.de/10005449024

Outcomes of Pharmacological and Surgical Treatment for Obesity

Cerulli, Jennifer; Malone, Margaret - In: PharmacoEconomics 14 (1998) 3, pp. 269-283

management of obesity. Clinical outcomes assessed include weight changes over time and the effects of weight loss on blood … evaluation was based on a Medline search of published data between January 1990 and January 1998. Obesity affects 65 million … adults in the US. Estimates based on 1990 data suggest that obesity and comorbid illness contributed to $US46 billion in …

Persistent link: https://www.econbiz.de/10005449067

The Cost Effectiveness of Orlistat in a 1-Year Weight-Management Programme for Treating Overweight and Obese Patients in Sweden: A Treatment Responder Approach

Hertzman, Peter - In: PharmacoEconomics 23 (2005) 10, pp. 1007-1020

Objective: To calculate the cost effectiveness (from the Swedish healthcare perspective) of orlistat plus diet for an obese and overweight population in a 1-year weight-management responder programme versus a 1-year weight-management programme based on diet only. As a reference, orlistat plus...

Persistent link: https://www.econbiz.de/10005590553

Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders

Krol, Marieke; Papenburg, Joc; Koopmanschap, Marc; … - In: PharmacoEconomics 29 (2011) 7, pp. 601-619

Background:Background: When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the...

Persistent link: https://www.econbiz.de/10011005068

Is There a Role for Pharmacoeconomics in Developing Countries?

Harper, Jonathan R. - In: PharmacoEconomics 29 (2011) 5, pp. 435-436

Persistent link: https://www.econbiz.de/10011005069

Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review

Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34

In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic evidence is lacking on superiority of one agent in terms of...

Persistent link: https://www.econbiz.de/10011005070

Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre

Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777

Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...

Persistent link: https://www.econbiz.de/10011005071

Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets

Augestad, Liv Ariane; Rand-Hendriksen, Kim; … - In: PharmacoEconomics 30 (2012) 12, pp. 1203-1214

Background:Background: National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices...

Persistent link: https://www.econbiz.de/10011005072

1
2
3
4
5
6
7
8
9
10
Next
Last